Thursday, February 28, 2019 Daily Archives

Under fire, BMS insists $74bn Celgene deal ‘next step in proven strategy’

by

Bristol-Myers Squibb has dismissed claims by investor groups that its proposed acquisition of Celgene “is poorly conceived and ill-advised.†In January, Bristol-Myers Squibb (BMS) announced it had entered into an agreement to buy Celgene for $74 billion (€65 billion). But this week Starboard Value LP, which holds a stake of 1.63 million shares in BMS, criticized the deal in a letter to fellow shareholders. “We believe that Bristol-Myers is deeply undervalued and the recent announcement of the Company’s proposed acquisition…

February 28, 2019

Continuous Chromatography: Experts Weigh in on the Possibilities and the Reality

by , and

Discussions of continuous processing in the biopharmaceutical industry are an important part of current efforts toward intensifying bioproduction and bioprocessing. Biomanufacturers are looking at all components of their development and manufacturing processes for ways to reduce the size of their facilities, lower costs, and increase speed and flexibility of operations. Increasing options for and availability of single-use technologies have been major enablers of myriad attempts to improve efficiencies. Although the general consensus may still be that single-use components are more…

February 28, 2019

Novartis licenses Factor XI Ab to Blackstone-backed $250m bio firm

by

Newly launched firm Anthos Therapeutics has licensed Novartis candidate MAA868 and will look to develop it for cardiovascular disorders. Novartis retains a minority stake in the Blackstone-backed biopharma. Private investment firm Blackstone Life Sciences launched this week Anthos Therapeutics, a biopharma company focused on advancing next-generation targeted therapies for high-risk cardiovascular patients. The company, backed by $250 million (€220 million) of Blackstone funds, will look to a Novartis candidate as a potential anti-thrombotic therapy to treat patients currently underserved by…

February 28, 2019

Hey Big Vendor: With GE, Danaher becomes largest bioprocess player

by

The $21.4 billion addition of GE Healthcare’s Biopharma business will complement Pall’s technologies to bring biomanufacturers a fully end-to-end bioprocessing offering. BioProcess Insider reported the news that Danaher Corporation has agreed to buy the Biopharma division of GE Healthcare’s Life Sciences business for approximately $21.4 billion (€18.9 billion) on Monday. If the deal is completed, it will be the biggest merger in the bioprocessing space, dwarfing Danaher’s previous $13.8 billion takeover of Pall Corporation in 2015, and the similar size…

February 28, 2019